Connected Thinking

Leading Voices

Latest News

Bispecific Antibodies For Follicular Lymphoma

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Follicular Lymphoma (FL) is a type of cancer of the white blood cells (WBCs). It is slow growing and often does not cause any symptoms in patients. Traditional therapies, while effective against many cases of FL, can often fail in the long term. The disease can […]

Learn More

Durvalumab Improves Survival in Liver and Biliary Tract Cancers

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Liver cancers including hepatocellular carcinoma (HCC) and biliary tract or bile duct cancers (BTC) are rare but deadly, with only 20% and 9% of the patients surviving at 5 years respectively. In a welcome and much-needed development, studies show that the immunotherapy drug Durvalumab (tradename Imfinzi) […]

Learn More

A Better Medication For Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma: Zanubrutinib

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. In two large clinical trials, zanubrutinib (tradename Brukinsa) outperformed Ibrutinib and Bendamustine-Rituximab, which are common drugs used as a first treatment for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). This led to its swift approval by the FDA for clinical use in these cancers. […]

Learn More

Zanubrutinib: A Better Medication For Chronic Lymphocytic Leukemias & Small Lymphocytic Lymphomas

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. In two large clinical trials, zanubrutinib (tradename Brukinsa) outperformed Ibrutinib and Bendamustine-Rituximab, two common first-line treatments for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). This led to its swift approval by the FDA for clinical use in the community. Zanubrutinib belongs to a class […]

Learn More

New Developments In Tyrosine Kinase Inhibitor Therapy (TKI) for Chronic Myeloid Leukemia (CML)

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Tyrosine Kinase Inhibitors (TKIs) are a highly specific treatment for Chronic Myeloid Leukemia (CML). CML is a type of blood cancer that arises in the cells of the red-spongy tissue lining, called the bone marrow, the insides of large bones. TKIs are a form of targeted […]

Learn More

Distinguishing Between Acute And Chronic Myeloid Leukemia

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are two types of leukemias or blood cell cancers that originate in the myeloid tissue, commonly known as the bone marrow. Due to certain mutations or changes within the DNA of the bone marrow cells, one or […]

Learn More

Monitoring Patients During Oral Treatment for CML

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. These days, the standard of care for chronic myeloid leukemia (CML) is a type of targeted therapy known as tyrosine kinase inhibitors (TKIs). When a patient begins this treatment, they need to be monitored regularly to ensure their body is tolerating the drugs. “When someone starts […]

Learn More

The Powerful Drugs for Chronic Myeloid Leukemia: Tyrosine Kinase Inhibitors (TKIs)

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Tyrosine Kinase Inhibitors (TKIs) are targeted therapies that have had great success in treating chronic myeloid leukemia (CML). Before these drugs were available, the standard of care of CML was a stem cell transplant, but TKIs have changed the game. “A stem cell transplant (or allogeneic […]

Learn More